A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the response rate to TPI 287 in patients
with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.